Gilead Files 8-K on Material Definitive Agreement, Other Events

Ticker: GILD · Form: 8-K · Filed: 2024-02-12T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, corporate-event

TL;DR

**Gilead just signed a big deal or had a major event; details to follow.**

AI Summary

Gilead Sciences, Inc. filed an 8-K on February 12, 2024, reporting an "Entry into a Material Definitive Agreement" and "Other Events" that occurred on February 11, 2024. This filing indicates a significant new agreement or event that could impact the company's operations or financial standing. For investors, this matters because material agreements can signal new partnerships, acquisitions, or divestitures, potentially affecting future revenue streams, market position, or strategic direction.

Why It Matters

This filing signals a potentially significant business development for Gilead, which could influence its financial performance and strategic direction, directly impacting shareholder value.

Risk Assessment

Risk Level: medium — The filing indicates a material event but lacks specific details, creating uncertainty about its potential positive or negative impact on the company.

Analyst Insight

A smart investor would monitor Gilead's subsequent announcements or filings for specific details regarding the 'Material Definitive Agreement' to assess its potential impact on the company's financials and strategic direction.

Key Players & Entities

Forward-Looking Statements

FAQ

What specific event triggered Gilead Sciences, Inc. to file this 8-K?

The 8-K was triggered by an "Entry into a Material Definitive Agreement" and "Other Events" as reported under Item 1.01 and Item 8.01, respectively, with the earliest event occurring on February 11, 2024.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on February 11, 2024.

What is the filing date of this 8-K for Gilead Sciences, Inc.?

The filing date for this 8-K by Gilead Sciences, Inc. was February 12, 2024.

Under which items of Form 8-K did Gilead Sciences, Inc. report this information?

Gilead Sciences, Inc. reported this information under "ITEM INFORMATION: Entry into a Material Definitive Agreement" and "ITEM INFORMATION: Other Events."

What is Gilead Sciences, Inc.'s business address as stated in the filing?

Gilead Sciences, Inc.'s business address is 333 LAKESIDE DR, FOSTER CITY, CA 94404.

From the Filing

0000950103-24-002027.txt : 20240212 0000950103-24-002027.hdr.sgml : 20240212 20240212083751 ACCESSION NUMBER: 0000950103-24-002027 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20240211 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240212 DATE AS OF CHANGE: 20240212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 24617510 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 dp206638_8k.htm FORM 8-K false 0000882095 CA 0000882095 2024-02-11 2024-02-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES  SECURITIES AND EXCHANGE COMMISSION  Washington, D.C. 20549   ____________________________   FORM 8-K ____________________________   CURRENT REPORT   Pursuant to Section 13 or 15(d) of  The Securities Exchange Act of 1934   DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): FEBRUARY 11, 2024    ____________________________   GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter)   ____________________________   Delaware 0-19731 94-3047598 (State or other jurisdiction  of incorporation)  (Commission File No.) (IRS Employer  Identification No.)   333 LAKESIDE DRIVE , FOSTER CITY , CALIFORNIA (Address of principal executive offices)   94404 (Zip Code)   (650) 574-3000   (Registrant’s telephone number, including area code)   Not Applicable  (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  ☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  ☒   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  ☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which  registered  Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐            Item 1.01 Entry into a Material Definitive Agreement   On February 11, 2024, Gilead Sciences, Inc., a Delaware corporation (“ Parent ” or “ Gilead ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), among Parent, CymaBay Therapeutics, Inc., a Delawar

View on Read The Filing